Cargando…
ARL3 activation requires the co-GEF BART and effector-mediated turnover
The ADP-ribosylation factor-like 3 (ARL3) is a ciliopathy G-protein which regulates the ciliary trafficking of several lipid-modified proteins. ARL3 is activated by its guanine exchange factor (GEF) ARL13B via an unresolved mechanism. BART is described as an ARL3 effector which has also been implica...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817177/ https://www.ncbi.nlm.nih.gov/pubmed/33438581 http://dx.doi.org/10.7554/eLife.64624 |
_version_ | 1783638585041223680 |
---|---|
author | ElMaghloob, Yasmin Sot, Begoña McIlwraith, Michael J Garcia, Esther Yelland, Tamas Ismail, Shehab |
author_facet | ElMaghloob, Yasmin Sot, Begoña McIlwraith, Michael J Garcia, Esther Yelland, Tamas Ismail, Shehab |
author_sort | ElMaghloob, Yasmin |
collection | PubMed |
description | The ADP-ribosylation factor-like 3 (ARL3) is a ciliopathy G-protein which regulates the ciliary trafficking of several lipid-modified proteins. ARL3 is activated by its guanine exchange factor (GEF) ARL13B via an unresolved mechanism. BART is described as an ARL3 effector which has also been implicated in ciliopathies, although the role of its ARL3 interaction is unknown. Here, we show that, at physiological GTP:GDP levels, human ARL3GDP is weakly activated by ARL13B. However, BART interacts with nucleotide-free ARL3 and, in concert with ARL13B, efficiently activates ARL3. In addition, BART binds ARL3GTP and inhibits GTP dissociation, thereby stabilising the active G-protein; the binding of ARL3 effectors then releases BART. Finally, using live cell imaging, we show that BART accesses the primary cilium and colocalises with ARL13B. We propose a model wherein BART functions as a bona fide co-GEF for ARL3 and maintains the active ARL3GTP, until it is recycled by ARL3 effectors. |
format | Online Article Text |
id | pubmed-7817177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-78171772021-01-21 ARL3 activation requires the co-GEF BART and effector-mediated turnover ElMaghloob, Yasmin Sot, Begoña McIlwraith, Michael J Garcia, Esther Yelland, Tamas Ismail, Shehab eLife Biochemistry and Chemical Biology The ADP-ribosylation factor-like 3 (ARL3) is a ciliopathy G-protein which regulates the ciliary trafficking of several lipid-modified proteins. ARL3 is activated by its guanine exchange factor (GEF) ARL13B via an unresolved mechanism. BART is described as an ARL3 effector which has also been implicated in ciliopathies, although the role of its ARL3 interaction is unknown. Here, we show that, at physiological GTP:GDP levels, human ARL3GDP is weakly activated by ARL13B. However, BART interacts with nucleotide-free ARL3 and, in concert with ARL13B, efficiently activates ARL3. In addition, BART binds ARL3GTP and inhibits GTP dissociation, thereby stabilising the active G-protein; the binding of ARL3 effectors then releases BART. Finally, using live cell imaging, we show that BART accesses the primary cilium and colocalises with ARL13B. We propose a model wherein BART functions as a bona fide co-GEF for ARL3 and maintains the active ARL3GTP, until it is recycled by ARL3 effectors. eLife Sciences Publications, Ltd 2021-01-13 /pmc/articles/PMC7817177/ /pubmed/33438581 http://dx.doi.org/10.7554/eLife.64624 Text en © 2021, ElMaghloob et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Biochemistry and Chemical Biology ElMaghloob, Yasmin Sot, Begoña McIlwraith, Michael J Garcia, Esther Yelland, Tamas Ismail, Shehab ARL3 activation requires the co-GEF BART and effector-mediated turnover |
title | ARL3 activation requires the co-GEF BART and effector-mediated turnover |
title_full | ARL3 activation requires the co-GEF BART and effector-mediated turnover |
title_fullStr | ARL3 activation requires the co-GEF BART and effector-mediated turnover |
title_full_unstemmed | ARL3 activation requires the co-GEF BART and effector-mediated turnover |
title_short | ARL3 activation requires the co-GEF BART and effector-mediated turnover |
title_sort | arl3 activation requires the co-gef bart and effector-mediated turnover |
topic | Biochemistry and Chemical Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817177/ https://www.ncbi.nlm.nih.gov/pubmed/33438581 http://dx.doi.org/10.7554/eLife.64624 |
work_keys_str_mv | AT elmaghloobyasmin arl3activationrequiresthecogefbartandeffectormediatedturnover AT sotbegona arl3activationrequiresthecogefbartandeffectormediatedturnover AT mcilwraithmichaelj arl3activationrequiresthecogefbartandeffectormediatedturnover AT garciaesther arl3activationrequiresthecogefbartandeffectormediatedturnover AT yellandtamas arl3activationrequiresthecogefbartandeffectormediatedturnover AT ismailshehab arl3activationrequiresthecogefbartandeffectormediatedturnover |